MeTis Lipid 1 is an ionizable lipid featuring a pentacyclic core with geminal dimethyl groups and symmetrical C9 alkyl chains developed by Metis Pharm. According to Patent WO 2025/140421 A1, Lipid 1 demonstrated exceptional biological performance including: the highest SARS-CoV-2 neutralization titer (NT50 1:2146, 5.7-fold higher than ALC0315), potent humoral immunity with COVID-19 IgG titers reaching 1:1,000,000 post-boost and exclusive validation for VZV-gE IgG (1:1,000,000), favorable biophysical properties (124.5 nm LNP diameter, 0.2 PDI, 85% encapsulation efficiency), and excellent safety profile (hERG IC₅₀ >30 μM, Mini-Ames negative), establishing it as the lead compound in nucleic acid vaccine delivery.
